are able to reprogram tumor cells, turning them into functional cDC1s, which are more effective than other DC subtypes at cross-presenting antigens and inducing antigen-specific T cell responses.

The other approach involves injecting dendritic cells expressing tumor-associated antigens subcutaneously, to prevent cancer relapse through a vaccination approach (Fig. 1). “The principle ...

Merck & Co. has penned a $300 million biobucks-per-product deal with cancer biotech Epitopea to identify previously secret antigens that could form the backbone of off-the-shelf immunotherapies.